ArticleBMC ophthalmology2022
Screening for retinopathy of prematurity in North China.
Article in BMC ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Epidemiology of retinopathy of prematurity (ROP) in Northwest China: a decade-long retrospective single-center analysis (2015-2024).Frontiers in pediatrics · 2026Article
- Risk factors for retinopathy of prematurity development and progression in the Philippines.International journal of ophthalmology · 2026Article
- Development of a non-invasive diagnostic model for severe Retinopathy of Prematurity integrating clinical and platelet data.Scientific reports · 2025Article
- Diagnosis and Risk Factors in Retinopathy of Prematurity: A Five-Year Single-Center Descriptive Study.Life (Basel, Switzerland) · 2025Article
- Clinical effects of the 2021 update of the Turkish retinopathy of prematurity guideline.BMC ophthalmology · 2025Article
- Editorial to the Special Issue "Retinopathies: A Challenge for Early Diagnosis, Innovative Treatments, and Reliable Follow-Up".Medicina (Kaunas, Lithuania) · 2025Article
- Screening for retinopathy of prematurity in China: a five-year cohort study in seven screening centers.BMC ophthalmology · 2025Article
- Retrospective validation of the postnatal growth and retinopathy of prematurity criteria in a Chinese cohort.Frontiers in pediatrics · 2025Article
- Multi-omics integration identifies key biomarkers in retinopathy of prematurity through 16S rRNA sequencing and metabolomics.Frontiers in microbiology · 2025Article
- Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center.Journal of clinical medicine · 2024Article
- Epidemiology and distribution of 207 rare diseases in China: A systematic literature review.Intractable & rare diseases research · 2024Review
- Incidence and Risk Factors for Retinopathy of Prematurity in a Tertiary Hospital in China.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Possibilities of Influencing Procedural Pain Associated with Premature Newborn Retinopathy Screening with Oral Clonidine.Children (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo analyze the incidence and severity of retinopathy of prematurity (ROP) in north China, and to evaluate the effectiveness of different ROP screening criteria. PATIENTS AND
methodsThe screening data of premature infants were collected from 2016 to 2021. The severity of ROP was graded according to the International Classification of Retinopathy of Prematurity (2005). And the treatment for ROP followed the Early Treatment for Retinopathy of Prematurity Cooperative Group. The effects of gestational age (GA) and birth weight (BW) on the incidence and severity of ROP were evaluated. The screening data were also analyzed using different ROP screening guidelines.
resultsA total of 4069 infants underwent ROP screening, and 728 infants (17.9%) were diagnosed with ROP. Of those, 78 infants (1.9%) received treatments. Gestational age and BW showed significant differences between infants with and without ROP (29.1 ± 2.1w vs. 32.9 ± 2.6w, p < 0.001; 1362.7 ± 427.3 g vs. 1751.9 ± 509.4 g, p < 0.001; respectively). Fifty-six infants (7.69%), 188 infants (25.82%), and 104 infants (14.29%) in all infants with ROP would have been missed according to the China, USA, and UK screening guidelines respectively. If GA ≤ 33 weeks and/or BW ≤ 2100 g were considered as screening criteria, only one infant (0.14%) with critical systemic illness was missed diagnosed with severe ROP.
conclusionGestational age and BW are major risk factors for the incidence and severity of ROP. And the incidence and treatment rate of ROP in Tianjin is similar to that reported in the other regions of China. Modified ROP screening criteria were considered to be more effective in Tianjin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.